Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs State Street SPDR S&P Biotech ETF — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.3 (market cap $40.01B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 4× State Street SPDR S&P Biotech ETF's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.14% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.

HLNXBI
Market Cap
$40.01B$10.11B
Volume
19,985,93512,903,266
Sector
HealthBroad Market / Factor
52-Week High
$11.27$169.55
52-Week Low
$8.70$104.99
Typical Hold Time
0 Days37 Days
Enterprise Value
$49.79B—
Dividend Yield
2.14%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.

Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN
100% Buy0% Sell
Avg holding period · 0 Days
XBI
100% Buy0% Sell
Avg holding period · 37 Days

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI →